article

Assays In-Depth Focus 2020

4
SHARES
Share via

Posted: 24 March 2020 | | No comments yet

Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.

Included in this in-depth focus:

  • In vitro platforms for de-risking nephrotoxicity during drug development
    If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current cell line and animal models are insufficient and how suitable pre-clinical testing with human tissue models can reduce this risk.
  • Genomic assays: on the brink of revolutionising human healthcare
    Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.











To read this in-depth focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Bellbrook Labs

Send this to a friend